These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18393849)

  • 1. Novel molecules targeting dyslipidemia and atherosclerosis.
    Tavridou A; Manolopoulos VG
    Curr Med Chem; 2008; 15(8):792-802. PubMed ID: 18393849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging targets for the treatment of dyslipidemia.
    Tavridou A; Ragia G; Manolopoulos VG
    Curr Med Chem; 2011; 18(6):909-22. PubMed ID: 21182475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
    Rached FH; Chapman MJ; Kontush A
    Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents to manage dyslipidemias and impact atherosclerosis.
    Nachimuthu S; Raggi P
    Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):209-17. PubMed ID: 17017903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
    Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
    Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid pharmacotherapy for treatment of atherosclerosis.
    Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R
    Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
    Hausenloy DJ; Yellon DM
    Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities.
    Kypreos KE; Bitzur R; Karavia EA; Xepapadaki E; Panayiotakopoulos G; Constantinou C
    Angiology; 2019 Mar; 70(3):197-209. PubMed ID: 29862840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting high-density lipoproteins: update on a promising therapy.
    Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
    Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging options in the treatment of dyslipidemias: a bright future?
    Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):247-70. PubMed ID: 21323473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention challenges: the era of atherosclerosis regression.
    Tardif JC
    Can J Cardiol; 2006 Aug; 22 Suppl C(Suppl C):27C-30C. PubMed ID: 16929388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.